ENERGIZE THE FIGHT.
Our Mito Champions
Need to Connect with Us?
Call the Support Line: (888) 900-6486
UMDF Signs on to Everylife Letter to FDA Encouraging More Engagement with Patient Groups
Ask Congress to review the FDA’s decision not to approve elamipretide for Barth Syndrome and encourage thorough review and reform of the FDA’s rare disease therapy evaluation process
June Newsletter: FDA News, accelerators Finalists, Mito Med 2025, and More
Signup to receive the UMDF newsletter in your email monthly at umdf.org/newsletter-signup.